Intensity Therapeutics reports positive early data from INVINCIBLE-4 study of INT230-6

Intensity Therapeutics announced positive early clinical data for its lead candidate INT230-6 from the INVINCIBLE-4 (SAKK 66/22) Phase 2 study. Data from the first seven patients in Cohort A showed 5 of 7 (71%) achieved a pathological complete response in the breast and affected lymph nodes.

Detected & updated continuously · Source: Nebula